Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
See Attems and Jellinger (doi:10.1093/brain/awx360) for a scientific commentary on this article.Cognitive changes occurring throughout the pathogenesis of neurodegenerative diseases are directly linked to synaptic loss. We used in-depth proteomics to compare 32 post-mortem human brains in the prefrontal cortex of prospectively followed patients with Alzheimer's disease, Parkinson's disease with dementia, dementia with Lewy bodies and older adults without dementia. In total, we identified 10 325 proteins, 851 of which were synaptic proteins. Levels of 25 synaptic proteins were significantly altered in the various dementia groups. Significant loss of SNAP47, GAP43, SYBU (syntabulin), LRFN2, SV2C, SYT2 (synaptotagmin 2), GRIA3 and GRIA4 were further validated on a larger cohort comprised of 92 brain samples using ELISA or western blot. Cognitive impairment before death and rate of cognitive decline significantly correlated with loss of SNAP47, SYBU, LRFN2, SV2C and GRIA3 proteins. Besides differentiating Parkinson's disease dementia, dementia with Lewy bodies, and Alzheimer's disease from controls with high sensitivity and specificity, synaptic proteins also reliably discriminated Parkinson's disease dementia from Alzheimer's disease patients. Our results suggest that these particular synaptic proteins have an important predictive and discriminative molecular fingerprint in neurodegenerative diseases and could be a potential target for early disease intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In both conditions, these altered functions largely originate from synaptic dysfunction relating to altered synaptic proteomes31,32.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies of postmortem human brains have found the significant association between cognitive decline and the loss of synaptic proteins in PFC, such as SNAP25, SNAP47, SV2C, SYT2 and GRIA3 253,254”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [253]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Synapses are the hub of neuron communications, and their degeneration is widely observed across multiple neurodegenerative diseases and increasingly recognized as a central cause of dementia 2,4,5,8,16 .”
From NAD+ hydrolase Sarm1 is a key driver of synapse degeneration and memory loss in Alzheimer’s disease (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“suggesting that these PFC synaptic markers are predictive molecular fingerprint for neurodegenerative diseases”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [253]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · cited 1×
“Cognitive data were available for most patients and consisted of the last Mini-Mental State Examination (MMSE) scores, assessed in most cases within 1–2 years before death (Folstein et al., 1975) and MMSE decline calculated as average decline over a period of clinical observation of 8–10 years.”
MethodSystematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
Universal sample preparation method for proteome analysis
Wiśniewski, J. R., Zougman, A., Nagaraj, N., & Mann, M. (2009) · Nature Methods · doi:10.1038/nmeth.1322 · Cited by 8,352
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 2×
“, 2010), a characteristic feature in Alzheimer’s disease (Terry et al., 1991; Honer, 2003) and increasing attention is now being devoted to their role in synucleinopathies (Aarsland et al.”
BackgroundThe molecular biology of memory storage: a dialogue between genes and synapses
Kandel, E. R. (2001) · Science · doi:10.1126/science.1067020 · Cited by 3,917
GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists
Eden, E., Navon, R., Steinfeld, I., Lipson, D., & Yakhini, Z. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-48 · Cited by 3,356
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658
Semi-supervised learning for peptide identification from shotgun proteomics datasets
Käll, L., Canterbury, J. D., Weston, J., Noble, W. S., & MacCoss, M. J. (2007) · Nature Methods · doi:10.1038/nmeth1113 · Cited by 2,424
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
A draft map of the human proteome
Kim, M.-S., Pinto, S. M., Getnet, D., Nirujogi, R. S., Manda, S. S., Chaerkady, R., Madugundu, A. K., Kelkar, D. S., Isserlin, R., Jain, S., et al. (2014) · Nature · doi:10.1038/nature13302 · Cited by 2,198 · cited 1×
“Recent advances in mass spectrometry-based proteomics offer a reliable molecular phenotype comparison between diseased and control cases allowing in-depth coverage of quantitative changes (Kim et al., 2014).”
BackgroundMembrane Fusion: Grappling with SNARE and SM Proteins
Südhof, T. C., & Rothman, J. E. (2009) · Science · doi:10.1126/science.1161748 · Cited by 2,027
ProteoWizard: open source software for rapid proteomics tools development
Kessner, D., Chambers, M., Burke, R., Agus, D., & Mallick, P. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn323 · Cited by 2,024
The Prefrontal Cortex—An Update
Fuster, J. M. (2001) · Neuron · doi:10.1016/s0896-6273(01)00285-9 · Cited by 1,775
Prevalence and Characteristics of Dementia in Parkinson Disease: An 8-Year Prospective Study
Aarsland, D., Andersen, K., Larsen, J. P., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,401 · cited 1×
“Cognition gradually declines in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia leading to loss of function in everyday life, reduced quality of life, and increased mortality (Aarsland et al., 2003; McKeith et al., 2005; Maalouf et al., 2011).”
BackgroundSelf-citationMS-GF+ makes progress towards a universal database search tool for proteomics
Kim, S., & Pevzner, P. A. (2014) · Nature Communications · doi:10.1038/ncomms6277 · Cited by 1,098
The worldwide costs of dementia 2015 and comparisons with 2010
Wimo, A., Guerchet, M., Ali, G., Wu, Y., Prina, A. M., Winblad, B., Jönsson, L., Liu, Z., & Prince, M. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.150 · Cited by 1,066 · cited 1×
“The pandemic increase of dementia, hampering daily living of many millions, carries serious implications for society (Wimo et al., 2017).”
BackgroundSelf-citationSynaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., DeKosky, S. T., & Mufson, E. J. (2007) · Neurology · doi:10.1212/01.wnl.0000260698.46517.8f · Cited by 824 · cited 1×
“Both Alzheimer’s disease and Lewy body diseases are characterized by substantial synaptic loss, which to date serves as the best correlate with cognitive impairment (Terry et al., 1991; Scheff et al., 2007; Pienaar et al., 2012).”
BackgroundAltered expression of synaptic proteins occurs early during progression of Alzheimer's disease
Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W., & Morris, J. C. (2001) · Neurology · doi:10.1212/wnl.56.1.127 · Cited by 720
OpenMS: a flexible open-source software platform for mass spectrometry data analysis
Röst, H. L., Sachsenberg, T., Aiche, S., Bielow, C., Weisser, H., Aicheler, F., Andreotti, S., Ehrlich, H.-C., Gutenbrunner, P., Kenar, E., et al. (2016) · Nature Methods · doi:10.1038/nmeth.3959 · Cited by 693 · cited 1×
“Quantification of TMT10plex reporter ions was done using OpenMS project’s IsobaricAnalyzer (Rost et al., 2016) (v2.”
MethodLewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
Compta, Y., Parkkinen, L., O'Sullivan, S. S., Vandrovcova, J., Holton, J. L., Collins, C., Lashley, T., Kallis, C., Williams, D. R., de Silva, R., et al. (2011) · Brain · doi:10.1093/brain/awr031 · Cited by 583
A Scalable Approach for Protein False Discovery Rate Estimation in Large Proteomic Data Sets
Savitski, M. M., Wilhelm, M., Hahne, H., Kuster, B., & Bantscheff, M. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.046995 · Cited by 445
Differential expression of synaptic vesicle protein 2 (SV2) isoforms
Bajjalieh, S., Frantz, G., Weimann, J., McConnell, S., & Scheller, R. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05223.1994 · Cited by 440 · cited 1×
“Additional proteins with a potential role in cognitive impairment such as the members of the SNARE family, synaptotagmins (SYT), PSD95 and synaptic vesicle 2 (SV2) proteins have also been incriminated in this captivatingly complicated process of synaptic plasticity (Bajjalieh et al., 1994; Xu et al., 2007; Dun et al.,…”
BackgroundDecreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease
Goetzl, E. J., Kapogiannis, D., Schwartz, J. B., Lobach, I. V., Goetzl, L., Abner, E. L., Jicha, G. A., Karydas, A. M., Boxer, A., & Miller, B. L. (2016) · The FASEB Journal · doi:10.1096/fj.201600816r · Cited by 398 · cited 1×
“22 In line with this, SYT2 levels have also been shown to be decreased in plasma neuronal-derived exosomes (Goetzl et al., 2016).”
BackgroundAbdi, F., Quinn, J. F., Jankovic, J., McIntosh, M., Leverenz, J. B., Peskind, E., Nixon, R., Nutt, J., Chung, K., Zabetian, C., et al. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9309 · Cited by 384 · cited 2×
“, 2016), only few studies have been conducted in dementia with Lewy bodies (Abdi et al., 2006; Barthelemy et al., 2016; Biemans et al., 2016).”
BackgroundExpression Mechanisms Underlying NMDA Receptor‐Dependent Long‐Term Potentiation
NICOLL, R. A., & MALENKA, R. C. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb11320.x · Cited by 365
Neuropathology of dementia in Parkinson's disease: A prospective, community‐based study
Aarsland, D., Perry, R., Brown, A., Larsen, J. P., & Ballard, C. (2005) · Annals of Neurology · doi:10.1002/ana.20635 · Cited by 348 · cited 1×
“, 1991; Honer, 2003) and increasing attention is now being devoted to their role in synucleinopathies (Aarsland et al., 2005; Compta et al., 2011; Howlett et al., 2015; Bereczki et al., 2016).”
BackgroundSelf-citationXu, J., Mashimo, T., & Südhof, T. C. (2007) · Neuron · doi:10.1016/j.neuron.2007.05.004 · Cited by 336
Identification of Candidate Gene Variants in Korean MODY Families by Whole-Exome Sequencing
Shim, Y. J., Kim, J. E., Hwang, S.-K., Choi, B. S., Choi, B. H., Cho, E.-M., Jang, K. M., & Ko, C. W. (2015) · Hormone Research in Paediatrics · doi:10.1159/000368657 · Cited by 325
Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-53 · Cited by 293 · cited 1×
“Whereas some explorative proteomic studies have already been performed in Alzheimer’s disease and Parkinson’s disease (Abdi et al., 2006; Blennow and Zetterberg, 2013; Brinkmalm et al., 2014; Halbgebauer et al., 2016), only few studies have been conducted in dementia with Lewy bodies (Abdi et al.”
BackgroundCerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease
Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J. Q., Weiner, M. W., Shaw, L. M., & Mattsson, N. (2015) · Brain · doi:10.1093/brain/awv267 · Cited by 279
HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics
Branca, R. M. M., Orre, L. M., Johansson, H. J., Granholm, V., Huss, M., Pérez-Bercoff, Å., Forshed, J., Käll, L., & Lehtiö, J. (2014) · Nature Methods · doi:10.1038/nmeth.2732 · Cited by 269 · cited 6×
“1 Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Novum, Stockholm, Sweden 2 Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden 3 King’s College London, Wolfson Centre for Age-…”
MethodInfluentialSelf-citationSjögren, M., Minthon, L., Davidsson, P., Granérus, A. K., Clarberg, A., Vanderstichele, H., Vanmechelen, E., Wallin, A., & Blennow, K. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070079 · Cited by 239 · cited 1×
“Likewise, CSF levels of GAP43 were found to be altered in separate studies in Parkinson’s disease (Sjogren et al., 2000) and in Alzheimer’s disease (Sjogren et al.”
AMPA receptor trafficking and the mechanisms underlying synaptic plasticity and cognitive aging
Henley, J. M., & Wilkinson, K. A. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.1/jhenley · Cited by 236
LTP Requires a Unique Postsynaptic SNARE Fusion Machinery
Jurado, S., Goswami, D., Zhang, Y., Molina, A. J. M., Südhof, T. C., & Malenka, R. C. (2013) · Neuron · doi:10.1016/j.neuron.2012.11.029 · Cited by 232
Increased CSF neurogranin concentration is specific to Alzheimer disease
Wellington, H., Paterson, R. W., Portelius, E., Törnqvist, U., Magdalinou, N., Fox, N. C., Blennow, K., Schott, J. M., & Zetterberg, H. (2016) · Neurology · doi:10.1212/wnl.0000000000002423 · Cited by 232 · cited 1×
“The potential use of key synaptic proteins as biomarkers has recently come in the spotlight of discussions in various dementias (Bereczki et al., 2016; Wellington et al., 2016).”
BackgroundBlennow, K., Bogdanovic, N., Alafuzoff, I., Ekman, R., & Davidsson, P. (1996) · Journal of Neural Transmission · doi:10.1007/bf01273157 · Cited by 206 · cited 1×
“It has been shown that synaptic loss is a better correlate of cognitive impairment in Alzheimer’s disease than the hallmark tau and amyloid-b pathologies (Blennow et al., 1996; Masliah et al., 2001).”
BackgroundRegional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias
Howlett, D. R., Whitfield, D., Johnson, M., Attems, J., O'Brien, J. T., Aarsland, D., Lai, M. K. P., Lee, J. H., Chen, C., Ballard, C., et al. (2015) · Brain Pathology · doi:10.1111/bpa.12182 · Cited by 194
Self-citationKirvell, S. L., Esiri, M., & Francis, P. T. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03935.x · Cited by 187 · cited 1×
“Preparation of tissue for western blotting and ELISA analyses was performed as previously described (Kirvell et al., 2006).”
MethodSelf-citationFerrer, I., Santpere, G., Arzberger, T., Bell, J., Blanco, R., Boluda, S., Budka, H., Carmona, M., Giaccone, G., Krebs, B., et al. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31802c3e7d · Cited by 175 · cited 2×
“Although we selected Alzheimer’s disease cases with low a-synuclein pathology, we did not observe any difference in the overall levels of monomeric a-synuclein protein, neither between Parkinson’s disease dementia and Alzheimer’s disease nor between dementia with Lewy bodies and Alzheimer’s disease, which could be par…”
BackgroundSynaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia
Bereczki, E., Francis, P. T., Howlett, D., Pereira, J. B., Höglund, K., Bogstedt, A., Cedazo‐Minguez, A., Baek, J., Hortobágyi, T., Attems, J., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.04.005 · Cited by 167 · cited 7×
“While general synaptic loss is a common feature of dementia, specific pre- and postsynaptic proteins such as Rab3A, SNAP25, synaptophysin crucial for vesicle trafficking, exo- and endocytosis have been found specifically altered in neurodegenerative diseases (Whitfield et al., 2014; Bereczki et al., 2016) along with N…”
BackgroundMethodResultInfluentialSelf-citationDoes α‐synuclein modulate dopaminergic synaptic content and tone at the synapse?
Sidhu, A., Wersinger, C., & Vernier, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-1112rev · Cited by 163
Whitfield, D., Vallortigara, J., Alghamdi, A., Howlett, D. R., Hortobágyi, T., Johnson, M., Attems, J., Newhouse, S., Ballard, C. G., Thomas, A. J., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.015 · Cited by 152 · cited 4×
“While general synaptic loss is a common feature of dementia, specific pre- and postsynaptic proteins such as Rab3A, SNAP25, synaptophysin crucial for vesicle trafficking, exo- and endocytosis have been found specifically altered in neurodegenerative diseases (Whitfield et al., 2014; Bereczki et al., 2016) along with N…”
BackgroundResultInfluentialSelf-citationBarthélemy, N. R., Gabelle, A., Hirtz, C., Fenaille, F., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Junot, C., Becher, F., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150962 · Cited by 139
Pathology of presynaptic proteins in Alzheimer's disease: more than simple loss of terminals
Honer, W. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.04.005 · Cited by 135
Sjögren, M., Davidsson, P., Gottfries, J., Vanderstichele, H., Edman, Å., Vanmechelen, E., Wallin, A., & Blennow, K. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051268 · Cited by 122 · cited 1×
“, 2000) and in Alzheimer’s disease (Sjogren et al., 2001; Goetzl et al., 2016).”
Moya-Alvarado, G., Gershoni-Emek, N., Perlson, E., & Bronfman, F. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r115.053330 · Cited by 117
Revolutionizing Alzheimer's disease and clinical trials through biomarkers
Mattsson, N., Carrillo, M. C., Dean, R. A., Devous, M. D., Nikolcheva, T., Pesini, P., Salter, H., Potter, W. Z., Sperling, R. S., Bateman, R. J., et al. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.001 · Cited by 102 · cited 2×
“Of note, even if a biomarker has shown high specificity and sensitivity, its utility as a theragnostic biomarker is not guaranteed (Mattsson et al., 2015).”
BackgroundSandberg, A., Lindell, G., Källström, B. N., Branca, R. M., Gemzell‐Danielsson, K., Dahlberg, M., Larson, B., Forshed, J., & Lehtiö, J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.016998 · Cited by 100 · cited 1×
“Although originally designed for array data, SAM has been shown to be valid also for LC-MS/MS data (Roxas and Li, 2008; Sandberg et al., 2012).”
MethodSelf-citationRemnestål, J., Just, D., Mitsios, N., Fredolini, C., Mulder, J., Schwenk, J. M., Uhlén, M., Kultima, K., Ingelsson, M., Kilander, L., et al. (2016) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201500150 · Cited by 98 · cited 5×
“The technological advance in proteomics analyses has provided high-throughput screening methods in the quest for biomarkers of neurodegenerative disorders in postmortem as well as in CSF or blood-based samples.”
BackgroundInfluentialShi, M. Y., Bradner, J. M., Bammler, T. K., Eaton, D. L., Zhang, J., Ye, Z., Wilson, A. M., Montine, T. J., Pan, C., & Zhang, J. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081019 · Cited by 90 · cited 1×
“This finding is in agreement with a previous proteomics study (Shi et al., 2009) carried out in Parkinson’s disease patients while another proteomics study in patients with Parkinsonism-dementia complex of Guam reported accumulation of a-synuclein levels (Yang et al.”
ResultSynaptic proteins in CSF relate to Parkinson’s disease stage markers
Bereczki, E., Bogstedt, A., Höglund, K., Tsitsi, P., Brodin, L., Ballard, C., Svenningsson, P., & Aarsland, D. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0008-2 · Cited by 72
Self-citationThe application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease
Blennow, K., & Zetterberg, H. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.012 · Cited by 69 · cited 1×
“Whereas some explorative proteomic studies have already been performed in Alzheimer’s disease and Parkinson’s disease (Abdi et al., 2006; Blennow and Zetterberg, 2013; Brinkmalm et al., 2014; Halbgebauer et al., 2016), only few studies have been conducted in dementia with Lewy bodies (Abdi et al.”
BackgroundSynaptic Proteins and Choline Acetyltransferase Loss in Visual Cortex in Dementia With Lewy Bodies
Mukaetova-Ladinska, E. B., Andras, A., Milne, J., Abdel-All, Z., Borr, I., Jaros, E., Perry, R. H., Honer, W. G., Cleghorn, A., Doherty, J., et al. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31827c5710 · Cited by 62 · cited 1×
“(Gottschall et al., 2010; Mukaetova-Ladinska et al., 2013; Howlett et al., 2015; Vallortigara et al., 2014; Whitfield et al., 2014), our results provide support to the link between cognitive performance and synaptic protein loss in Lewy body dementia.”
ResultSignificance analysis of microarray for relative quantitation of LC/MS data in proteomics
Roxas, B. A., & Li, Q. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-187 · Cited by 58 · cited 1×
“Although originally designed for array data, SAM has been shown to be valid also for LC-MS/MS data (Roxas and Li, 2008; Sandberg et al., 2012).”
MethodHalbgebauer, S., Öckl, P., Wirth, K., Steinacker, P., & Otto, M. (2016) · Movement Disorders · doi:10.1002/mds.26635 · Cited by 56 · cited 1×
“Whereas some explorative proteomic studies have already been performed in Alzheimer’s disease and Parkinson’s disease (Abdi et al., 2006; Blennow and Zetterberg, 2013; Brinkmalm et al., 2014; Halbgebauer et al., 2016), only few studies have been conducted in dementia with Lewy bodies (Abdi et al.”
BackgroundBiemans, E. A. L. M., Verhoeven‐Duif, N. M., Gerrits, J., Claassen, J. A. H. R., Kuiperij, H. B., & Verbeek, M. M. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.017 · Cited by 47 · cited 1×
“, 2016), only few studies have been conducted in dementia with Lewy bodies (Abdi et al., 2006; Barthelemy et al., 2016; Biemans et al., 2016).”
BackgroundNeuropathological correlates of volumetric MRI in autopsy-confirmed Lewy body dementia
Burton, E. J., Mukaetova-Ladinska, E. B., Perry, R. H., Jaros, E., Barber, R., & O'Brien, J. T. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.015 · Cited by 43 · cited 1×
“The marked reductions of synaptic proteins in patients with dementia with Lewy bodies and Parkinson’s disease dementia could reflect a greater frontal degeneration in Lewy body dementia in comparison with Alzheimer’s disease, which usually affects the prefrontal cortex less than other medial and lateral temporal areas…”
BackgroundDementia with Lewy Bodies: Clinical Features and Treatment
Campbell, S., Stephens, S., & Ballard, C. G. (2001) · Drugs & Aging · doi:10.2165/00002512-200118060-00002 · Cited by 33
Self-citationSynaptic Protein Alterations in Parkinson’s Disease
Pienaar, I. S., Burn, D. J., Morris, C. M., & Dexter, D. T. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8226-9 · Cited by 32 · cited 1×
“Both Alzheimer’s disease and Lewy body diseases are characterized by substantial synaptic loss, which to date serves as the best correlate with cognitive impairment (Terry et al., 1991; Scheff et al., 2007; Pienaar et al., 2012).”
BackgroundLee, C.-Y., Lee, C., Shih, C., & Liou, H. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.08.006 · Cited by 27 · cited 1×
“, 2016) along with NMDA and AMPA receptors, PSD95 and neurogranin (Lipton and Rosenberg, 1994; Lee et al., 2008; Whitfield et al., 2014; Bereczki et al., 2016) playing a role in long-term potentiation (Fig.”
BackgroundVallortigara, J., Rangarajan, S., Whitfield, D., Alghamdi, A. A., Howlett, D. R., Hortobágyi, T., Johnson, M. A., Attems, J., Ballard, C. G., Thomas, A. J., et al. (2014) · F1000Research · doi:10.12688/f1000research.3786.1 · Cited by 27 · cited 2×
“As the levels of CAMK2 and neurogranin have already been assessed in this cohort (Vallortigara et al., 2014; Bereczki et al., 2016), we selected eight additional differentially regulated synaptic proteins based on their function, fold change, and antibody avail-”
MethodResultSelf-citationPanel of synaptic protein ELISAs for evaluating neurological phenotype
Gottschall, P. E., Ajmo, J. M., Eakin, A. K., Howell, M. D., Mehta, H. N., & Bailey, L. A. (2010) · Experimental Brain Research · doi:10.1007/s00221-010-2182-x · Cited by 26 · cited 2×
“Several studies have shown that changes in synaptic function are associated with alterations in the concentration of synaptic proteins (Gottschall et al., 2010), a characteristic feature in Alzheimer’s disease (Terry et al.”
BackgroundResultHeterozygous deletion of the LRFN2 gene is associated with working memory deficits
Thévenon, J., Souchay, C., Seabold, G. K., Dygai‐Cochet, I., Callier, P., Gay, S., Corbin, L., Duplomb, L., Thauvin‐Robinet, C., Masurel, A., et al. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.221 · Cited by 23 · cited 1×
“Likewise, deletion of LRFN2 localized both to the presynaptic and postsynaptic membrane has been linked to selective working memory and executive deficits, impaired intellectual functioning and auditoryverbal problems (Thevenon et al., 2016).”
BackgroundYang, W. J., Woltjer, R. L., Sokal, I., Pan, C., Wang, Y., Brodey, M., Peskind, E. R., Leverenz, J. B., Zhang, J., Perl, D. P., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070015 · Cited by 23
An update on the diagnosis and management of dementing conditions.
Maalouf, M., Ringman, J. M., & Shi, J. (2011) · PubMed · Cited by 23
The t-SNARE Complex: A Close Up
Dun, A. R., Rickman, C., & Duncan, R. R. (2010) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-010-9599-4 · Cited by 18 · cited 1×
“Additional proteins with a potential role in cognitive impairment such as the members of the SNARE family, synaptotagmins (SYT), PSD95 and synaptic vesicle 2 (SV2) proteins have also been incriminated in this captivatingly complicated process of synaptic plasticity (Bajjalieh et al., 1994; Xu et al., 2007; Dun et al.,…”
Background
Cited by
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
Cai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
Rodent models for Alzheimer disease
Götz, J., Bodea, L.-G., & Goedert, M. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0054-8 · Cited by 394
Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease
Bridi, J. C., & Hirth, F. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00080 · Cited by 378
“Studies investigating levels of synaptic proteins belonging to the SNARE complex in PD, PD with dementia (PDD) and DLB post-mortem samples also reported misregulation of proteins belonging to the SNARE complex (Kramer and Schulz-Schaeffer, 2007; Dijkstra et al., 2015; Bereczki et al., 2016, 2018).”
BackgroundThe clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328
“10 CONFIDENTIAL Other synaptic proteins including SNAP25, RAB3A, GAP43, AMPA receptor subunits, and a number of other proteins also show promise as CSF biomarkers of synaptic damage and loss (24,25,124,125).”
Background
Metadata
- Authors
- Bereczki, E., Branca, R. M., Francis, P. T., Pereira, J. B., Baek, J.-H., Hortobágyi, T., Winblad, B., Ballard, C., Lehtiö, J., & Aarsland, D.
- Affiliations
- Karolinska Institutet (SE)
- Science for Life Laboratory (SE)
- King's College London (GB)
- University of Debrecen (HU)
- Corresponding author
- Bereczki, Erika
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01-09
- Volume
- 141
- Issue
- 2
- Pages
- 582-595
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC5837272
- OpenAlex
- W2782564735
- Cited by
- 220
- References
- 71
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 31 · 2023: 25 · 2022: 29 · 2021: 32 · 2020: 36 · 2019: 21 · 2018: 17
- FWCI
- 17.06
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- Alzheimerfonden
- Parkinsonfonden
- Stohnes Stiftelse
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- synaptic proteins, cognitive decline, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease dementia, dementia with Lewy bodies, prefrontal cortex, SV2C, GRIA3, synaptotagmin 2, protein biomarkers, differential diagnosis
- MeSH terms
- Aged, Aged, 80 and over, Brain, Cognition Disorders, Female, Gene Expression Regulation, Humans, Male, Membrane Proteins, Microtubule-Associated Proteins, Nerve Tissue Proteins, Neurologic Examination, Neuropsychological Tests, Synapses, Neurodegenerative Diseases, Proteomics, Intracellular Signaling Peptides and Proteins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.